Please wait

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

X0202 SCHEDULE 13D/A 0001740791 XXXXXXXX LIVE 5 Ordinary Shares, no par value per share (including Ordinary Shares represented by American Depositary Shares at a 1-to-1 ratio) 09/30/2026 false 0001631487 M2R51X124 CollPlant Biotechnologies Ltd. 4 Oppenheimer, Weizmann, Science Park Rehovot L3 7670104 Jonathan M. Nathan, Adv. 972-3-610-3100 Meitar Law Offices 1 Ariel Sharon Street Givatayim L3 5320048 0001740791 N Ami Sagy PF N L3 163709.00 0.00 163709.00 0.00 163709.00 N 5.7 IN Row 13: The percent of class set forth in row 13 is based on 2,866,715 ordinary shares outstanding as of September 30, 2026, which information was provided by the Issuer in response to the Reporting Person's request and which reflects the Issuer's 1-for-10 reverse share split that was effective on September 4, 2026. Ordinary Shares, no par value per share (including Ordinary Shares represented by American Depositary Shares at a 1-to-1 ratio) CollPlant Biotechnologies Ltd. 4 Oppenheimer, Weizmann, Science Park Rehovot L3 7670104 Ami Sagy 66 Pinkas Street, Tel Aviv, Israel 62157 The Reporting Person serves as manager of the Sagy Group, which manages bank charges and reduces financial costs for medium to large organizations and institutions. The principal address of the offices at which the Reporting Person is employed is 84 Ben-Tzvi Road, Tel Aviv 68104, Israel. During the last five years, the Reporting Person has not been convicted in a criminal proceeding. During the last five years, the Reporting Person was not a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. The Reporting Person is a citizen of Israel. No funds were used in connection with any transactions reported in this Amendment No. 5, which is being filed to report a decrease in the Reporting Person's percentage beneficial ownership resulting from issuances of Ordinary Shares by the Issuer. The Reporting Person is filing this Amendment No. 5 to Schedule 13D ("Amendment No. 5") to report that, as a result of issuances of Ordinary Shares by the Issuer since the filing of Amendment No. 4 to Schedule 13D on November 28, 2025, his beneficial ownership percentage has decreased to approximately 5.7% of the outstanding Ordinary Shares. The Reporting Person has not acquired or disposed of any Ordinary Shares since the filing of Amendment No. 4. The Reporting Person holds the Ordinary Shares reported herein for investment purposes only, and in the ordinary course, and not with the purpose or effect of changing or influencing control of the Issuer, and is therefore eligible to begin reporting his beneficial ownership on Schedule 13G under Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Reporting Person may, from time to time, based on various factors, acquire additional Ordinary Shares of the Issuer or sell Ordinary Shares, on the open market or in privately negotiated transactions. Except as described above, as of the filing of this Amendment No. 5, the Reporting Person does not have any definitive plans or proposals which relate to or would result in any of the following: (a) the acquisition by the Reporting Person of additional Ordinary Shares, or the disposition of Ordinary Shares that he holds; (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) a sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) a change in the present board of directors or management of the Issuer, including any plan or proposal to change the number or term of directors or to fill any existing vacancies on the board; (e) a material change in the present capitalization or dividend policy of the Issuer; (f) any other material change in the Issuer's business or corporate structure; (g) changes in the Issuer's memorandum of association or articles of association or other actions which may impede the acquisition of control of the Issuer by any person; (h) causing the ADSs to be delisted from the Nasdaq Capital Market or any other national securities exchange on which they may be listed in the future, or to cease to be authorized to be quoted in any inter-dealer quotation system of a registered national securities association in which they may be quoted in the future; (i) causing the ADSs to become eligible for termination of registration pursuant to Section 12(g)(4) of the Exchange Act; or (j) any action similar to any of those enumerated above. The responses of the Reporting Person to Rows (11) and (13) of the cover page of this Amendment No. 5 are incorporated herein by reference. The aggregate percentage of Ordinary Shares reported as beneficially owned by the Reporting Person in this Amendment No. 5 was calculated based on 2,866,715 ordinary shares outstanding as of September 30, 2026, which information was provided by the Issuer to the Reporting Person upon his request and which reflects the Issuer's 1-for-10 reverse share split that was effective on September 4, 2026. The responses of the Reporting Person to Rows (7) through (10) of the cover page of this Amendment No. 5 are incorporated herein by reference. The Reporting Person has not effected any transactions in the Ordinary Shares during the 60 days preceding this Amendment No. 5. Not applicable. Not applicable. None. None. Ami Sagy /s/ Ami Sagy Ami Sagy 10/08/2026